Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. Co. is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. We show 29 historical shares outstanding datapoints in our ALLO shares outstanding history coverage, used to compute ALLO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ALLO market cap history over the course of time is important for investors
interested in comparing ALLO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ALLO versus a peer is one thing; comparing
ALLO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ALLO can fluctuate over the course of history.
With this page we aim to empower investors researching ALLO by allowing them to research the ALLO market cap history. |
Free ALLO Email Alerts:
Video: The Importance of Market Cap
